Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

595 trials

NCT07851493
Recruiting
Exercise Phenotyping Prior to Chemotherapy in Newly Diagnosed Multiple Myeloma (MM-Exercise)
Not applicable · Germany · 1 site
Registry update: 5 Oct 2026
NCT07637578
Recruiting
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
Phase 2 · United States · 6 sites
Registry update: 4 Sept 2026
NCT07009899
Recruiting
BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)
Phase 2 · United States · 1 site
Registry update: 4 Nov 2026
NCT07624513
Recruiting
D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM
Phase 3 · United States · 3 sites
Registry update: 9 Oct 2026
2025-524793-42-00
Recruiting
Phase 2 Randomized, Double-blind, Placebo-controlled Study of Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma
Phase 2 · Spain, France, Greece, Hungary, Portugal, Sweden · 37 sites
Registry update: 11 Sept 2026
NCT07850284
Recruiting
SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders
Not applicable · United States · 1 site
Registry update: 30 Sept 2026
2025-525105-20-00
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Phase 1/2 · Belgium, Czechia, Germany, France, Greece, Italy, Poland, Portugal, Sweden · 33 sites
Registry update: 15 Jul 2026
NCT07221032
Recruiting
FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma
Phase 1 · United States · 1 site
Registry update: 4 Nov 2026
NCT07772024
Recruiting
Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma
Phase 3 · United States · 1 site
Registry update: 19 Aug 2026
NCT07715630
Recruiting
In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma
Phase 1 · China · 1 site
Registry update: 20 Jul 2026
NCT07341867
Recruiting
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Phase 1 · United States · 2 sites
Registry update: 2 Nov 2026
NCT07681596
Recruiting
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Phase 1/2 · Australia, United States · 12 sites
Registry update: 15 Oct 2026
NCT07649681
Recruiting
Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention
Not applicable · Germany · 6 sites
Registry update: 20 Aug 2026
2023-510560-12-00
Recruiting
Phase II Open-Label, Single Arm, Multicenter Study of Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma
Phase 2 · Spain · 9 sites
Registry update: 23 Jul 2026
NCT07652281
Recruiting
A Clinical Study of SHR-5421 in Patients With Multiple Myeloma
Phase 1 · China · 1 site
Registry update: 30 Jul 2026
NCT07657312
Recruiting
Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma
Phase 2 · United States · 1 site
Registry update: 6 Oct 2026
NCT07609940
Recruiting
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
Phase 4 · United States · 7 sites
Registry update: 27 Oct 2026
NCT07665307
Recruiting
Delayed Toxicities Post-CAR-T
Not applicable · United States · 3 sites
Registry update: 10 Aug 2026
NCT07782944
Recruiting
CD38 Targeted -PET/ CT for Multiple Myeloma
Not applicable · China · 1 site
Registry update: 24 Aug 2026
NCT07409454
Recruiting
MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma
Phase 2 · China · 1 site
Registry update: 7 Aug 2026

Ordered by registry start date. Freshness and sponsorship never change the order.